Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings

Gigante, Angelo Fabio; Defazio, Giovanni; Asabella, Artor Niccoli; Superbo, Maria; Ferrari, Cristina; Liuzzi, Daniele; Iliceto, Giovanni; Livrea, Paolo; Rubini, Giuseppe

doi:10.1111/ane.12537

Cited by 9 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An observational study by Itti and co-workers showed a slower decrease in striatal [ 123 I]I-FP-CIT binding in 6 PD patients on nicotine therapy (-4%) than expected in PD patients (-10% per year) [ 101 ]. However, Gigante et al found a significantly lower [ 123 I]I-FP-CIT binding in the putamen of 11% in 13 current smokers compared to non-smokers [ 102 ]. Interestingly, the largest study by Thomsen and colleagues on this topic compared 64 non-smokers, 39 ex-smokers and 26 current smokers and found no statistically significant difference in striatal [ 123 I]I-FP-CIT binding between the different groups [ 103 ].…”

Section: Resultsmentioning

confidence: 99%

A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

Chahid

Sheikh²,

Mitropoulos³

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose In routine practice, dopamine transporter (DAT) imaging is frequently used as a diagnostic tool to support the diagnosis of Parkinson’s disease or dementia with Lewy bodies. In 2008, we published a review on which medications and drugs of abuse may influence striatal [123I]I-FP-CIT binding and consequently may influence the visual read of an [123I]I-FP-CIT SPECT scan. We made recommendations on which drugs should be withdrawn before performing DAT imaging in routine practice. Here, we provide an update of the original work based on published research since 2008. Methods We performed a systematic review of literature without language restriction from January 2008 until November 2022 to evaluate the possible effects of medications and drugs of abuse, including the use of tobacco and alcohol, on striatal DAT binding in humans. Results The systematic literature search identified 838 unique publications, of which 44 clinical studies were selected. Using this approach, we found additional evidence to support our original recommendations as well as some new findings on potential effect of other medications on striatal DAT binding. Consequently, we updated the list of medications and drugs of abuse that may influence the visual read of [123I]I-FP-CIT SPECT scans in routine clinical practice. Conclusion We expect that a timely withdrawal of these medications and drugs of abuse before DAT imaging may reduce the incidence of false-positive reporting. Nevertheless, the decision to withdraw any medication must be made by the specialist in charge of the patient’s care and considering the pros and cons of doing so.

show abstract

Section: Resultsmentioning

confidence: 99%

A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

Chahid

Sheikh²,

Mitropoulos³

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Diagnosis of PD is only possible through clinical signs and symptoms and by neuropathological findings at postmortem examination. By using a dopamine transporter single photon emission computed tomography (DaT-SPECT), we recently reported a widespread reduced striatal uptake in PD patients [2,3]. Nevertheless, there is no specific laboratory test available for PD, therefore, selective biomarkers to assist in the diagnosis of PD are needed.…”

Section: Introductionmentioning

confidence: 99%

Plasma levels of Clusterin are representative of the early phase of the neurodegenerative process in Parkinson’s disease

Polimeno¹,

Asabella²,

Mazzocca³

et al. 2018

J Clin Mol Med

View full text Add to dashboard Cite

Background/Aim: There is no reliable diagnostic test for Parkinson's disease (PD) despite many attempts to identify specific biomarkers for early diagnose of disease. Different patterns of protein expression in cerebrospinal fluid, including the apolipoproteinJ/Clusterin (CLU), have been reported in patients with PD. CLU is implicated in many biological processes, including aging, oxidative stress and apoptosis. A colocalization of CLU with α-synuclein, a presynaptic neuronal protein, in the cortical bodies of Lewy has been shown in patients with PD. Aim of this study was to test the hypothesis of CLU as a circulating biomarker in a cohort of patients with PD.Materials/Methods: Ninety-six patients with PD and eighty-four age and sex matched healthy subjects (HS) were enrolled. Plasma levels of CLU were determined and a correlation with motor and neuropathological parameters of PD patients was performed.Results/Conclusions: A significant increase in blood levels of CLU in PD patients, compared to HS, in subjects younger than 60 years of age (PD: 283 ± 149 µg/ ml, HS: 106 ± 74 µg/ml; p=2.7x10 -4 ) was detected. No statistically significant difference was observed in subjects older than 60 years of age. Furthermore, a significant inverse correlation between CLU blood levels and the Mini Mental State Examination (MMSE) was evidenced. The increased levels of CLU in younger PD patients may have relevance as an early biomarker for PD. Determination of circulating levels of CLU may therefore facilitate an early diagnosis in patients with PD where clinical aspects are not emerged yet, thus allowing a timely therapeutic approach.

show abstract

Does smoking impact dopamine neuronal loss in de novo Parkinson disease?

Lee

Chung

et al. 2017

Annals of Neurology

View full text Add to dashboard Cite

This study analyzed data from dopamine transporter (DAT) positron emission tomographic scans of 282 male patients with de novo Parkinson disease to investigate whether smoking impacts striatal dopamine neuronal degeneration. Mean DAT activity in the posterior (p = 0.016) and ventral putamen (p = 0.028) was higher in 44 current smokers in comparison to 105 ex-smokers and 133 never-smokers. The severity of baseline motor deficits and the longitudinal increases in levodopa-equivalent doses during follow-up were similar among the 3 groups. These results suggest that current smoking, but not past smoking, protects dopamine neuronal degeneration in the sensorimotor striatum with no additional clinical benefits. Ann Neurol 2017;82:850-854.

show abstract

Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings

Cited by 9 publications

References 35 publications

A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

Plasma levels of Clusterin are representative of the early phase of the neurodegenerative process in Parkinson’s disease

Does smoking impact dopamine neuronal loss in de novo Parkinson disease?

Contact Info

Product

Resources

About